Ποια είναι η τιμή για Orchard Therapeutics plc (ORTX)

Η τιμή για Orchard Therapeutics plc (ORTX) είναι $16.70

Ποια είναι η κεφαλαιοποίηση αγοράς για Orchard Therapeutics plc (ORTX)

Η κεφαλαιοποίηση αγοράς για Orchard Therapeutics plc (ORTX) είναι $210.34M

Orchard Therapeutics plc (ORTX) Τιμή και Κεφαλαιοποίηση Αγοράς

Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.

Η τιμή για ORTX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$430,661 $210.34M	NVDA	$5.424T	+2,578,706.38%
$379,181 $210.34M	AAPL	$4.776T	+2,270,442.79%
$321,693 $210.34M	GOOG	$4.052T	+1,926,205.09%
$293,049 $210.34M	MSFT	$3.691T	+1,754,686.26%
$217,879 $210.34M	AMZN	$2.744T	+1,304,562.82%

Η τιμή για ORTX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$430,661 $210.34M